Lyra Therapeutics | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 25 K

Revenue: As of FY2025 Q3, the actual value is USD 25 K, missing the estimate of USD 154.25 K.

EPS: As of FY2025 Q3, the actual value is USD -3.38, beating the estimate of USD -5.255.

EBIT: As of FY2025 Q3, the actual value is USD -6.493 M.

Third Quarter 2025 Financial Highlights

Cash and Cash Equivalents

• As of September 30, 2025, cash and cash equivalents were $22.1 million, compared to $40.6 million at December 31, 2024.

Research and Development Expenses

• Decreased by $1.9 million from $5.9 million to $4.0 million for the three months ended September 30, 2025 compared to the same period in 2024.

General and Administrative Expenses

• Decreased by $1.7 million from $3.9 million to $2.2 million for the three months ended September 30, 2025 compared to the same period in 2024.

Restructuring Charges

• Incurred a restructuring credit of $21 thousand for the three months ended September 30, 2025, compared to a restructuring charge of $2.8 million for the same period in 2024.

Net Loss

• Net loss for the third quarter 2025 was $6.0 million, compared to $11.9 million for the same period in 2024.

Outlook / Guidance

• Lyra Therapeutics plans to conduct a new, confirmatory Phase 3 clinical trial of LYR-210 for CRS without nasal polyps, aiming for NDA submission. The company anticipates its cash and cash equivalents will fund operating expenses and capital expenditures into the third quarter of 2026.